key: cord-0850905-9b7sruy3 authors: Trilling, Mirko title: What the HEC happens around the heart during COVID-19? date: 2021-07-05 journal: Basic Res Cardiol DOI: 10.1007/s00395-021-00883-7 sha: 30a6b466ff3756fe655147af89d4b651ff32a3e3 doc_id: 850905 cord_uid: 9b7sruy3 nan The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged by the end of 2019 [28] and is currently causing a global pandemic. Amid the third wave of the pandemic, over 174 million laboratory-confirmed infections have occurred to date and more than 3.74 million people died in the context of a coronavirus infectious disease 2019 . Projections regarding undertesting, underreporting, and excess mortalities indicate that the true numbers of cases and fatalities are actually far higher. Despite the encouraging availability of very safe and effective vaccines, it will take a long time to overcome the medical, social, and economic consequences of the COVID-19 pandemic-especially in developing countries that struggle to provide their populations with sufficient vaccines. SARS-CoV-2 is a betacoronavirus belonging to the sarbecovirus subgenus and shares several virological as well as clinical aspects with the first severe acute respiratory syndrome virus that had caused a restricted epidemic in 2003 [13] . However, a distinctive feature of SARS-CoV-2 is its very efficient human-to-human transmission [23] . The most prominent disease manifestations caused by SARS-CoV-2 involve the respiratory tract. Usually, virus replication causes less severe symptoms when confined to the upper respiratory tract, whereas extensive virus replication in the lower respiratory tract can cause pneumonia, acute respiratory distress syndrome, and eventually death, especially in the elderly and individuals with pre-existing conditions. However, the SARS-CoV-2 tropisms and the organ manifestations of COVID-19 are far more complex: in addition to the respiratory tract, several other organs and tissues are also permissive for SARS-CoV-2 replication, resulting in a variety of different types of COVID-19 [8, 17] . SARS-CoV-2 is a cytopathic virus. Accordingly, its replication itself destroys host cells and impairs the functions of affected tissues. Unfortunately, critically ill patients have been found to suffer from severe COVID-19 at times when very little if any virus progeny was detectable in clinical swab samples and various body fluids. One reason is that the vigorous immune response stimulated by SARS-CoV-2 contributes to the pathophysiology of organ failure, e.g., through hyperinflammation [19] . Accordingly, patients in later stages of disease benefit clinically from anti-inflammatory drugs such as Dexamethasone [7] . Even after the acute infection has resolved, a significant proportion of patients, rather than recovering to their pre-COVID-19 health status, continue to suffer from various forms of long-COVID syndrome [3, 15] . In terms of aforementioned organ manifestations beyond the respiratory tract and the pathologic consequences of autodestructive inflammation as well as long-COVID, a central question is if SARS-CoV-2 can bug out in certain niches, in which the virus or at least virus-encoded antigens such as the spike (S) protein persist. Besides aforementioned other clinical features, SARS-CoV-2 causes a spectrum of cardiac and cardiovascular manifestations [10, 14, 20] . A study using cardiac magnetic resonance imaging showed an astonishing incidence of cardiac involvement in 78% and ongoing myocardial inflammation in 60% of patients who recently recovered from COVID-19 [18] . Upon SARS-CoV-2 infection, people with pre-existing cardiovascular diseases are at an increased risk of severe disease and death, and the coronavirus infection is associated with multiple cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism [4] . Given that the most relevant entry receptor of SARS-CoV-2, the human angiotensin-converting enzyme 2 (hACE2) [9] , is expressed in the endothelium of arteries and veins, COVID-19 has been described to be almost as much a vascular disease as it is a respiratory disease [2, 12] . In these regards, Stefanie Dimmeler and colleagues performed a comprehensive characterization of the SARS-CoV-2 permissiveness of various human endothelial cells Like all relevant research, this well-conducted study answers several important questions while also raising a number of intriguing new ones: how frequent and under which circumstances do SARS-CoV-2, and VOCs in particular, reach HCAECs in natura? To which extent do abortive HCAEC infections contribute to the known cardiovascular manifestations of COVID-19 [1, 5] ? Which post-entry mechanisms prevent productive SARS-CoV-2 replication in HCAECs? Does the S protein present in HCAEC result in immune responses mediated by described S-specific lymphocytes [6, 11, 21] or antibodies [24] [25] [26] ? Taken together, the study by Dimmeler and colleagues published in this issue of Basic Research in Cardiology [22] , in line with concordant research conducted by others in iPSC models [16, 27] , uncovers a remarkable aspect of the biology and the pathophysiology of COVID-19 by showing that SARS-CoV-2 is capable to cause abortive infections of human coronary artery endothelial cells. Funding Open Access funding enabled and organized by Projekt DEAL. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. COVID-19 and the Heart Cardiology and COVID-19 Persistent symptoms in patients after acute COVID-19 Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic Perspective: cardiovascular disease and the Covid-19 pandemic Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Dexamethasone in hospitalized patients with Covid-19 Extrapulmonary manifestations of COVID-19 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Clinical features of patients infected with 2019 novel coronavirus in Wuhan SARS-CoV-2-specific T cell memory is long-lasting in the majority of convalsecent COVID-19 individuals COVID-19 is, in the end, an endothelial disease Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV Cardiovascular complications in COVID-19 Covid-19: what do we know about "long covid SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19 Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm? Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants A crowned Killer's resume: genome, structure, receptors, and origin of SARS-CoV-2 Occurrence of COVID-19 symptoms during SARS-CoV-2 infection defines waning of humoral immunity SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids China Novel Coronavirus I, Research T (2020) A novel coronavirus from patients with pneumonia in China